Before I start, don’t forget my deal of the day! Today back by popular demand I have the TradeKing deal. Also, don’t forget if you have to make any type of purchase from Amazon simply follow my link here, any purchase will help GekkoWire out and there are no extra charges to you, just a simple click on a link!!!!
Get $50 when you open a TradeKing account today. » Read more: Arena Pharmaceuticals (ARNA): Run Down of FDA Cardiovascular Safety Guidance
| September 16, 2010 |
Before I start, don’t forget my deal of the day, today back by popular demand I have the TradeKing deal. Also, don’t forget if you have to make any type of purchase from Amazon simply follow my link here, any purchase will help GekkoWire out and there are no extra charges to you, » Read more: Arena, Vivus, Orexigen: A Must Read Article
Join Zecco Trading and get 20 free trades with bonus code “bonus1″
Arena Pharmaceuticals (ARNA):
Arena made a formal announcement this morning that the FDA has confirmed the scheduling of an Advisory hearing for their lead product Lorcaserin. The news isn’t really news to most investors however, as the date had already been released. » Read more: Daily Pharma Watch
Arena Pharmaceuticals (ARNA) Rough Share Price Target if Approved
Zacks Premium FULL ACCESS Membership – 30-day free trial
I have gotten a lot of questions about a target price for Arena or the market share for their drug Lorcaserin if it gets approved. I’ll be honest, I haven’t done a lot of due diligence into the pricing that Arena was looking to put on the drug, but previously I had done an analysis on Vivus for what kind of revenues that company might be expecting. » Read more: Arena Pharmaceuticals (ARNA) Rough Share Price Target if Approved
So yesterday I pulled a quote from Athersys SEC filings in which they directly criticized Lorcaserin’s selectivity to the 5HT2c receptors. But Athersys isn’t exactly being truthful with its investors because in fact Arena’s Lorcaserin shows extremely high selectivity to the 5HT2c receptor. Arena’s drug actually shows an 18 fold increase in selectivity towards 5HT2c than 5HT2a and a 104 fold increase in selectivity towards 5HT2c over 5HT2b. » Read more: Arena Pharmaceuticals (ARNA): Update Part IV
Arena Pharma ceuticals, Orexigen therapeutics, and Vivus Inc.
Alright pharma investors, today I have put together a brief cross comparison of efficacy statistics from the three competing obesity drug companies: Arena, Vivus, and Orexigen. Before I go any further I would like to point out that the data marked with a ** in the Orexigen portion of the analysis is from the “Intent to Treat Population,” which is a touchy measurement subject in Pharma analysis. » Read more: Arena Pharmaceuticals (ARNA) vs. Vivus Inc (VVUS) vs. Orexigen Therapeutics (OREX)
So before I get into this part of the Arena Lorcaserin analysis, I have decided to address a question that I actually receive a lot from investors new to pharma trading. I try to stay away from trading strategies as often as I can on my website, but I am often asked a lot about where I learned some of my valuation techniques and usually in the context of options pricing (this is because there is a ton of money to be made » Read more: Arena Pharmaceuticals: Locraserin and the Fallen Competitors: Analysis Part III
Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS), Orexigen Therapeutics (OREX)
Before I start I would like to point out that I have added a Amazon Store link on my website. The reason for the link is that in order to keep publishing my site for free I have to find ways to bring in additional revenues. So whenever you search Amazon from GekkoWire.com (here) and make a purchase some of the proceeds go to help support the site. This allows me to continue to keep bringing my readers all of the valuable Pharma Information for FREE! The prices are the same from my Amazon search engine, so you have nothing to lose! So remember if you have to make a purchase from Amazon, search for the products from here first, because it goes to support the site! Thanks for all of your help!
So I have gotten a lot of questions about what the actual guidance is from the FDA in regards to Weight Loss Drugs. Most of these questions stem from the lack of clarity of what the FDA wants to establish as the safety and efficacy of the drug. » Read more: FDA Weight Loss Guidance Explained Arena, Vivus, Orexigen
Arena Pharmaceuticals (ARNA): Lorcaserin Part I
With the negative vote at the FDA’s panel hearing last week for Vivus’ weight loss drug Qnexa, investors have turned a sharp eye towards Arena’s Locraserin. In the first part of this analysis I’ll go over what the drug is and how it works in simple terms, I’ll then move into all of the studies and data out there. » Read more: Arena Pharmaceuticals (ARNA): Lorcaserin Part I
© 2010 GekkoWire · Proudly powered by WordPress & Green Park 2 by Cordobo.
Valid XHTML 1.0 Transitional | Valid CSS 3
Twitter